Merck, Keytruda and patent

In patent clash over injectable Keytruda, Merck and Halozyme dig in for a fight
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.
New version of Merck's Keytruda faces possible patent battle, WSJ reports
Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle
The company has asked the U.S. patent office to reconsider patents that could prevent it from selling a new version of its drug Keytruda.
Merck’s Keytruda subject of brewing patent dispute with Halozyme, WSJ says
Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in
Merck’s Injectable Keytruda Plans Create Legal Dispute With Halozyme: WSJ
The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that convert intravenous drugs into injectable versions.
Merck injected version of Keytruda faces possible patent challenge: Report
Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent dispute, according to a report by The Wall Street Journal
Merck (MRK) Battling to Protect Key Cancer Drug as Patent Row Heats Up
Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a new version of
New version of Merck's cancer drug faces possible patent battle: reports
Halozyme Therapeutics claims Merck's new Keytruda version infringes on patents, requiring a licensing agreement, reports WSJ.
Merck set for patent battle with Halozyme over injectable Keytruda: WSJ
A new patent dispute is brewing between Halozyme Therapeutics (NASDAQ:HALO), a biotech focused on drug delivery technology, and Merck (NYSE:MRK) over an injectable version of the New Jersey-based pharma giant’s cancer blockbuster,
WebMD9d
How Keytruda Works for Renal Cell Carcinoma
How Does Keytruda Work for RCC? Some cancer cells have what are called checkpoint proteins known as PD-L1 on their cell surface. Some immune cells in our bodies called T cells have proteins on ...
pharmaphorum5d
Keytruda breaks new ground in cervical cancer
MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...
Becker's Hospital Review29d
Keytruda's looming patent expiry raises concerns: 5 notes
Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...
Reuters9d
Merck expects cancer therapy Keytruda to be part of government price setting in 2026
Feb 25 (Reuters) - Drugmaker Merck (MRK.N), opens new tab said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become ...